Deucravacitinib: Significantly Improved Symptoms and Signs of Psoriasis in Patients with Psoriasis

Kim Papp presents in this MEDtalk results from the phase III POETYK PSO-1 and POETYK PSO-2 trials related to the treatment of plaque psoriasis with the drug deucravacitinib. The trial showed improvement in all domains related to the signs and symptoms, and the improvement was sustained over time. In concordance with the clinical practice, the data supports the effectiveness of deucravacitinib in treating chronic plaque psoriasis.